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Abstract
Globally, influenza infection is a major cause of morbidity and mortality in the elderly, who are suggested to be the major
target group for trivalent influenza vaccine (TIV) vaccination by World Health Organization. In spite of an increasing trend in
vaccine coverage rates in many countries, the effect of vaccination among the elderly in reducing hospitalization and
mortality remains controversial. In this study, we conducted a historical cohort study to evaluate the temporal pattern of
influenza-associated morbidity among persons older than 64 years over a decade. The temporal patterns of influenza-
associated morbidity rates among the elderly older than 64 years indicated that Taiwan’s elderly P&I outpatient visits have
been decreasing since the beginning of the 1999–2000 influenza season; however, hospitalization has been increasing
despite significant increases in vaccine coverage. The propensity score logistic regression model was implemented to
evaluate the source of bias and it was found that the TIV-receiving group had a higher propensity score than the non-
receiving group (P,0.0001). In order to investigate the major factors affecting the temporal pattern of influenza-associated
morbidity, we then used the propensity score as a summary confounder in a multivariate Poisson regression model based
on the trimmed data. Our final models suggested that the factors affected the temporal pattern of morbidity differently. The
variables including co-morbidity, vaccination rate, influenza virus type A and B isolation rate were associated with increased
outpatient visits and hospitalization (p,0.05). In contrast, variables including high propensity score, increased 1uC in
temperature, matching vaccine strains of type A/H1N1 and type B were associated with decreased outpatient visits and
hospitalization (p,0.05). Finally, we assessed the impact of early appearance of antigenic-drifted strains and concluded that
an excess influenza-associated morbidity substantial trends toward higher P&I hospitalization, but not outpatient visits,
during the influenza season with early appearance of antigenic-drifted strains.
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Introduction
Globally, influenza infection is a major cause of morbidity and
mortality in the elderly[1]. The vaccines currently used against
seasonal influenza contain antigens against three influenza strains
(A/H1N1, A/H3N2 and B), which are altered yearly to target the
strains that are predicted to circulate in the upcoming season
(WHO)[2,3]. The yearly influenza vaccination of at-risk individuals
became common practice worldwide after the Second World War.
After 2000, more than 40 developed or rapidly developing countries
recommended vaccination to prevent influenza and its complica-
tions for ‘‘high risk’’ groups, such as the elderly (65 years or older),
patients with chronic conditions, and institutionalized popula-
tions[4]. Nevertheless, vaccination of the elderly remains contro-
versial. Since there is a gradual decline in immune competence with
age, immunogenicity and hence vaccine effectiveness in the elderly
are suboptimal[5,6]. In spite of an increasing trend in vaccine
coverage rate, pneumonia and influenza-associated hospitalization
and mortality among the elderly have continued to rise in Italy[7],
the United States[8] and South Korea[9]. Recent comprehensive
literature reviews, based on 75 studies conducted between 1966–
2009, revealed that the trivalent inactivated influenza vaccine (TIV)
has been proven effective in preventing laboratory-confirmed
influenza among healthy elderly[10]. However, there is strikingly
limited good-quality evidence and inconsistent results of the
effectiveness of influenza vaccination on complications such as
pneumonia, hospitalization and influenza-specific and overall
mortality, which can only be explained by bias of unknown origin.
Because influenza virus replication has an inherently high
mutation rate, the Taiwan Centers for Disease Control (Taiwan-
CDC) has coordinated a laboratory-based influenza virological
surveillance network (Lab-ISN) starting in 2000 for providing up-to-
date information on viral characteristics and activities[11,12]. In the
region of Southeast Asia, there is usually a gap of 1–2 years before
an epidemic strain is recommended by the World Health
Organization (WHO) to be the vaccine strain[13,14]. Recent
surveys of influenza viruses in Taiwan by hemagglutination (HA)
sequence comparisons have indicated a high rate of vaccine
mismatch and found that epidemic strains in Taiwan often became
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the vaccine strains 2–3 years later[12,15]. Generally, antigenic
alterations of local strains that make existing antibody levels in the
population no longer protective are considered to be related to
disease severity, increased medical utility and vaccine efficacy.
Assessment of influenza vaccine effectiveness is complicated by
the degree of match between vaccine and virus, which varies from
year to year with mismatches leading to lower vaccine efficacy[16].
Cross-reactivity and avidity of antibody after vaccination might
increase through repeated immunization[17]. However, the long-
term effect on the reduction of influenza-associated morbidity,
defined by medical uses including outpatient visits and hospitaliza-
tion, has not been evaluated in countries with early appearance of
vaccine-mismatched strains. The Taiwan program of targeted free
influenza vaccination for people with underlying medical disorders
was implemented since 1996 and further expanded in 1998 to
include all people older than 64 years. Vaccines are delivered in
health care settings by nurses or physicians, or in community
settings through public health departments. The vaccination rate
gradually increased from 9.9% in 1998 to 49.2% in 2007 with the
peak reaching 70% in 2004, which was approximately the target
level of 68.0% set by Taiwan-CDC for a 2010 national goal. We
conducted a historical cohort study to evaluate the influenza-
associated morbidity among persons older than 64 years over a
number of epidemic and nonepidemic years in the past decade. The
aims of this study were: (1) to evaluate the temporal pattern of
influenza-associated morbidity over the last decade, (2) to evaluate
the source of bias measured by propensity score and investigate the
major factors affecting the temporal pattern of influenza-associated
morbidity, (3) to assess the impact of early appearance of antigenic-
drifted strains on the excess influenza-associated morbidity.
Materials and Methods
Data Sources
The data used in this study were obtained from the National
Health Insurance (NHI) Research Database (NHIRD) in Taiwan
for the period 2000 to 2009. The NHI program has been
implemented in Taiwan since 1995, and the coverage rate was
96% of the whole population in 2000 and over 97% at the end of
2003, at which time more than 21.9 million inhabitants were
enrolled. For research purposes, exactly one million residents of
Taiwan who were enrolled in NHI in 2005 were randomly selected
by the National Health Research Institute in Taiwan, using
stratified sampling scheme to ensure the whole population was
well-represented. The individual healthcare records for each clinical
and hospital visit had been fully digitalized. It should be noted that
the rationale for using the NHIRD after 2000 is that, from Jan 1,
2000, according to the rules of the Bureau of NHI, the NHI data
were all encoded using the standardized International Classification
of Disease, 9 Revision, Clinical Modification (ICD-9-CM).
For each year we acquired the records of those aged 65 or older
from NHIRD, and we repeated the process by year from 1999 to
2008. As a result, 60,835 elderly patients (29,462 women and
31,373 men) were used in the analysis for 1999–2000, and the
sample size increased yearly to 118,737 (59,721 women and
59,016 men) in the 2008–2009 analysis. Annual influenza periods
were marked as beginning on September 1st and concluding on
August 31st of the following year.
Data on annual influenza vaccine strains (collected from the
WHO), dominant types/subtypes of influenza viruses for winter
epidemic seasons, and monthly influenza isolation rates for the 1999–
2000 through 2008–2009 influenza seasons were also collected by the
Lab-ISN from Taiwan-CDC. Comparisons of the antigenic match
between influenza vaccine strains and Taiwan’s dominant influenza
epidemic strains are summarized in Table S1 and the years with
early appearance of antigenic-drifted virus are also indicated.
Vaccination rate data were obtained from three different
codings of outpatient visit prescriptions including card sequel
number: IC01, ICD-9-CM code: V048, or case type: 92 from the
complete NHI claim database in Taiwan for the period 2000 to
2009 since the free vaccination program requires that all the
elderly older than 64 use an insurance card to receive vaccination.
The results are consistent with the vaccination rate data compiled
from local health bureaus by Taiwan-CDC.
Ethics Statement
For confidentiality and to comply with regulations on personal
privacy in Taiwan, all personal identification numbers in NHIRD
were encrypted by conversion into scrambled numbers before data
processing. Because the database used consists of de-identified
secondary data released for research purposes, this principle
complies with the Personal Information Protection Act in Taiwan,
and this study was exempt from full review by the Institutional
Review Board.
Study Design
We used a retrospective cohort study design to assess the effect
of the early appearance of antigenic-drifted strains and the
vaccination rate of Taiwan elderly-targeted free influenza vacci-
nation program on influenza-associated morbidity, defined by
health care uses including outpatient visits and hospitalization.
Although ecological studies do not permit inference to individuals,
this design was appropriate for evaluating the impact of a
population-level vaccination program on population outcomes
rather than the effect of vaccination on individual outcomes. To
assess outpatient visits, we included only one service claim per
patient per visit per day and excluded claims that were submitted
within 14 days of the last claims under the same ICD-9-CM.
Emergency room use was not included for analysis because there
were few cases annually.
Definitions
Influenza-associated morbidities are difficult to quantify because
influenza infections are typically not confirmed. Since morbidities
coded as influenza are known to underestimate the true burden of
influenza, we studied more broadly defined conditions. To better
evaluate influenza’s disease burden, we included all pneumonia
and influenza (P&I, ICD-9-CM: 480–487) from outpatient visits,
and hospital discharge diagnoses during the study period,
excluding admissions of nonresidents, transfers between institu-
tions, and readmissions within 1 week of discharge. Our case
definition did not include positive laboratory confirmation of
influenza virus; however, the influenza-associated morbidity peaks
during the periods when influenza virus activity increases (Fig 1).
Therefore, in order to increase the specificity of the identification
of cases hospitalized for influenza-related illness, our influenza-
associated outcomes were measured as the difference between
observed events and expected baseline events during periods of
peak influenza activity (defined below), which reflects the excess
number of events that occur because of influenza activity beyond
what would be expected from the background (baseline) rates.
Periods of peak influenza activity were defined separately for
each year, starting when the weekly percentage of tests positive for
influenza was greater than 10% and ending when the percentage
fell below that threshold for 2 consecutive weeks.
Underlying diseases were defined as having inpatient or
outpatient diagnosis of co-morbidity during the study period.
Co-morbidity included existing cardiovascular and other heart
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diseases (Treatment item #11), chronic bronchitis (Treatment
item #10), chronic obstructive pulmonary disease (COPD)
(Treatment item #21), bronchiectasis (Treatment item #22),
diabetes (Treatment item #01), hypertension (Treatment item
#02), and chronic glomerulonephritis (Treatment item #04).
Propensity Score
When examining the association between y (e.g., influenza-
associated morbidity) and x (e.g., vaccination rate), with numerous
potential confounders (z’s) that are correlated with both x and y, a
more plausible way to adjust for the z’s is by using a propensity score
instead. For dichotomous x, Rosenbaum et al suggested the logit
propensity score b(z) = Log(Pr(x = 1|z)/Pr(x = 0|z)). They had
proved that z and x are conditionally independent given b(z)[18].
Since TIV vaccination was preferentially recommended for high-risk
frail individuals at many sites including Taiwan, this ‘‘confounding
by indication’’ was known a priori that analysis of study outcomes
would have to take this source of potential bias into account.
Variables assessed as potential confounders were described as the
following. The demographical confounders include: age, gender,
geographic region of residence (North/Central/South/East as
previously described[19]), urbanization level of residence, and
individual socioeconomic status (SES). We used income-related
insurance payment amounts as a proxy measure of individual SES
at the time of diagnosis. The individuals were classified into three
groups: (1) low SES: lower than US$571 per month (New Taiwan
Dollar (,NT$20,000); (2) moderate SES: between US$571-1,141
per month (NT$20,000–40,000); and (3) high SES: US$1,142 per
month (.NT$40,000) or more. In accordance with Taiwan
National Health Research Institute publications[20], urbanization
levels in Taiwan are classified into 7 strata, with level 1 referring to
the ‘‘most urbanized’’ and level 7 referring to the ‘‘least urbanized’’
communities. Here, levels 6 and 7 were merged into a single group
and labeled as level 6 due to the small number of subjects.
We also acquired potential clinical confounders based on
clinical information for a one-year period. These clinical
confounders included recent transfusion (case type: 05), having
tuberculosis (case type: 06), having prescription for chronic
diseases (case type: 08–09), having rehabilitation, day-care or
long-term care (case type: 61–67), recent infectious diseases
including enterobiasis (ICD9: 127.4 or A076), gonorrhea or
urogenital gonorrhea (ICD9: 098), syphilis (ICD9: 097 or A060),
rubella (ICD9: 056 or A043), measles (ICD9: 055 or A042),
human immunodeficiency virus (HIV) infection (case type: V08),
varicella or chickenpox-related (ICD-9: 052 or 053), herpes
simplex related (ICD-9: 054), herpangina or hand-foot-and-mouth
disease related (ICD-9: 074), other viral infection (ICD-9: A049),
number of outpatient visits for URI (URI OPD#, ICD-9-CM
code: 460-466), recent intestinal disorder (ICD-9-CM code: 558.9
or A549) and clinical record of smoking abstention (case type: 77).
Potential confounding variables acquired based on the five-year
period preceding the vaccination included the number of
outpatient visits, the indicator of having catastrophic illness
(defined by NHI with more than 30 different types of diseases,
detailed upon request), and the cumulative number of comorbid-
ities of chronic conditions, such as hypertension (treatment item:
02), glomerulonephritis (treatment item: 04), COPD (treatment
item: 21), chronic bronchitis (treatment item: 10), diabetes
(treatment item: 01), cardiovascular disease (treatment item: 11),
and bronchiectasis (treatment item: 22). The ascertainment of the
above comorbidities was defined from .= 1 hospital discharge or
.= 2 ambulatory visits with a relevant principal or secondary
diagnosis code. The indicator variable of recent self-reported flu
symptoms was defined as having P&I one-month before and three
weeks after the vaccination date (for the vaccinated group) or the
first day when the free vaccination was offered (for the
unvaccinated group). All variables were acquired by tracking all
the ambulatory medical care and inpatient records in the NHI
database in the year before the index visit.
To cope with the large number of potential confounders, we used
propensity score stratification to create comparable cohorts with
different TIV rates. A propensity score logistic regression model was
conducted to estimate the probability of receiving TIV versus no
TIV. The analyses were carried out annually from 1999 Sep. to
2009 Aug. The logistic regressions were applied to fit the vaccination
indicator (1 = yes, 0 = no) on the selected confounders from above,
with both the following selection criteria satisfied: (1) is significant in
the logistic model, (2) is significantly correlated with the flu indicator
(outpatient visit or hospitalization) in chi-square tests.
When fitting the regressions yearly from 1999–2000 to 2008–
2009, we found that the selections of variables among the models
were quite consistent, with the only exception of Year 1999–2000,
which has two variable less than rest of the models (Table S3). The
commonly selected variables included geographic region, urban-
ization, socioeconomic status, numbers of URI, OPD in the
previous 6 months, number of comorbidities, number of outpa-
tient visits, having catastrophic illness, and recent intestinal
disorder. Based on the results of each model, the propensity score
for each person-season was calculated by inverting the estimated
logit into the conditional probability for receiving TIV.
logit(TIV)~log
^
P(TIV~1 Confounders)j
1{
^
P(TIV~1 Confounders)j
 !
~b0zb1|½Geographic region
zb2|½Urbanizationlevelzb3|½SES
zb4|½URIOPD#zb5|½Outpatient visits
zb6|½Number of comorbidities
zb7|½Catastrophic illness
zb8|½Recentintestinaldisorder
Propensity Score~
^
P(TIV~1 Confounders)~j exp(logit(TIV)
1zexp(logit(TIV)
The bold letters stand for the parametervectors
for multi{level variables
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ð1Þ
Figure 1. Study event rates among the elderly $65 years old over the study period from 1999–2000 to 2008–2009 influenza
seasons in Taiwan. Panel A and Panel B represents pneumonia and influenza (P&I)-related outpatient visit and hospitalization rates. The actual
observed events (Blue-shaded area), model-predicted events (Red line) and age-standardized events (black dashed line) are expressed as monthly
rates per 100. Panel C represents viral surveillance data expressed as the weekly percentage of tests positive for influenza viruses. Horizontal line sets
the cutoff of isolation rate $10% and the influenza epidemic months are shaded in blue. Panel D represents the annual trivalent influenza vaccine
(TIV) vaccination rate among the elderly in percentage. No free TIV vaccination was provided for the 5–19 age group during 1999,9–2007,8.
doi:10.1371/journal.pone.0084239.g001
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Data Analyses and Statistical Tests
We first calculated the crude influenza-associated morbidity rate
by using the total population aged $65 years as the denominator.
Total population was calculated by the population equal to or
greater than 65 years old based on the enrollment in NHI in
September each year. The age-standardized influenza-associated
morbidity rates were calculated based on the age distribution of
the world standard population in 2000 from the WHO. Next, we
analyzed the influenza-associated morbidity using a three-step
procedure. In countries located in sub-tropical regions, summer
influenza activity is occasionally observed although winter
influenza activity accounts for the major peak. Firstly, in order
to select proper annual cyclic or partition function for further
multivariate analysis, several Poisson regression models were tried
out first to fit the actual influenza activity peaks, including (1)
annual periodic cycle functions (i.e., sine-cosine function of
seasonal periodicity) and (2) time-trend functions (trisection,
quadric-partition, and quinquefid-partition, i.e., divide a 12
month period into 3, 4, or 5 equal parts). The dependent variable
was the weekly counts of influenza-associated events, stratified by
gender, age and comorbidity combination, and offset by the
sample size of each stratum. We then compared the Akaike’s
information criterion (AIC) and Bayesian information criterion
(BIC) among the models to determine the best-fitted one, and
chose the corresponding function for further analysis. As a result,
all the annual models indicate that quinquefid-partition function
has the best fit.
In the second step, the propensity score for each patient was
estimated using the model in (1). We then trimmed out the outlier
observations defined as those with propensity scores below the
lower or above the upper 2.5 tail-percentiles. Stu¨rmer et al
suggested that these observations are outside the primary area of
the overlap of the propensity score, and may increase residual
confounding during analysis[21]. To be used as a stratification
variable in the next step, the propensity score was divided into five
categories with equal proportions, such that Group 1 has the
lowest propensity score and serves as the baseline group.
In the third step, a multivariate Poisson regression approach was
used to model the natural logarithm of the expected counts of
outpatient visits as well as hospitalization due to P&I. The 10-year
data were stratified by the following explanatory variables: Age
(65–74, 75–84, 85+), gender, comorbidity indicator (yes vs. no),
year indicators (1999.9–2000.8 to 2008.9–2009.8), quinquefid
propensity and quinquefid annual cyclic periods (Nov.–Dec., Jan.–
Feb., Mar.–May, Jun.–Aug., Sep.–Oct.) which are suggested by
the result from Step 1. Besides those stratified variables, the
following continuous covariates were also incorporated into the
model: annual vaccination rate, average temperature within the
period, monthly virus isolation rates for different types/subtypes of
influenza viruses (A (H3N2), A (H1N1) and B respectively) and the
matching status of different vaccine strains for each type/subtype
in each of the studied years. Matching status for each type/subtype
of influenza viruses was defined based on the antigenic charac-
teristics of the hemagglutinin gene between the vaccine strain and
the dominant wild-type strain of that particular season in Taiwan
as published previously[15] and by Taiwan-CDC. The monthly
measured data, like temperature and the isolation rates, were
averaged over the correspondent period. Furthermore, a scale
parameter was added in the Poisson regression to adjust the
dispersed distributions. The analysis was implemented by SAS
(version 9.3; SAS Institute Inc, Cary, NC). The final model for
‘‘influenza-associated morbidity’’ was devised as follows:
log(Influenza{associated morbidity)
~b0zb1|½Agezb2|½Genderzb3|½Comoebidity
zb4|½Propensity Scorezb5|½Yearzb6|½Period
zb7|½Temperaturezb8|½Vaccination Rate
zb9|½INFA Isolation Rate
zb10|½INFB Isolation Rate
zb11|½A(H1N1){matching
zb12|½A(H3N2){matching
zb13|½B{matching
The bold letters stand for the parameter
vectorsfor multi{level variables
 !
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Influenza-Associated Excess Morbidities
To evaluate the impact of the early appearance of antigenic-
drifted strain on influenza-associated elderly morbidities, excess
morbidity (95% confidence interval) was calculated for each winter
and year. These excess morbidities including outpatient visits and
hospitalization were assessed by calculating the difference between
observed data and expected baselines that were derived from the
multivariate regression model (Figure 1). After calculating residual
morbidity for each month (differences between each winter’s
monthly observed influenza-associated morbidity and monthly
expected value [obtained from our multivariate modeled morbid-
ity baseline]), we replaced negative residuals (e.g. observed values
less than the expected value) with zero and summed up excess
morbidity for each influenza season. Epidemic (or annual) excess
including morbidity during epidemic periods defined by virus
isolation rate $10% or the whole year were calculated based on
each epidemic’s (or annual) total excess morbidity divided by the
total population aged $65 years. The mean values for each
epidemic and annual excess morbidity before and after peak
vaccination rate were evaluated by independent T-test.
Results
Temporal Patterns of Influenza-Associated Morbidity
Rates
Temporal patterns of influenza-associated morbidity rates
among the elderly older than 64 years indicate that Taiwan’s
elderly P&I outpatient visits have been decreasing since the
beginning of the 1999–2000 influenza season; however, the
hospitalization has been increasing despite significant increases
in vaccine coverage. As described in Figure 1A, the mean annual
P&I outpatient rate, 17.5 per 1000 during the 1999–2000 season,
gradually declined to 4.43 per 1000 during the 2008–2009 season.
However, the mean annual P&I hospitalization rate during the
1999–2000 season was 1.39 per 1000, which surged to 5.84 per
1000 (p,0.001) after the 2004–2005 season (after the peak
coverage rate of implementing a free TIV vaccination program)
and remained at a similar rate afterwards (Figure 1B). In addition
to this temporal pattern, seasonal cycles were also found for all
influenza-associated morbidity rates with peaks consistent with the
cyclic peaks of influenza activity based on Lab-ISN as shown in
Fig 1C. Noticeably, the yearly vaccination rates among the elderly
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older than 64 years of age suggested a gradually increasing pattern
from 11% during the 1999–2000 season to 60% during the 2003–
2004 season; however, the rate has gradually dropped to 40%
since then (Fig 1D).
Age-standardized rate also suggested that the outpatient visit
rate gradually decreased from 1.71% during the 1999–2000
season to 0.48% during the 2008–2009 season. In contrast, age-
standardized hospitalization rate revealed an increase since the
1999–2000 season with 0.09% and peaked at 0.36% during the
2004–2005 season (Fig 1).
Age-Specific Influenza-Associated Morbidity Rates
The decreasing patterns of outpatient rates were further
analyzed across all age strata. As shown in Fig 2A, the decreasing
patterns were consistent throughout the study period among all
four age groups (5–19, 65–74, 75–84, and 85+). Interestingly, the
outpatient visit rates among the elderly (65–74 and 75–84) were
was found to be lower than the rates among the young age group
(5–19) after the 2003–2004 season. This was consistent with the
increasing annual vaccination rate since 1999–2000 and reached
the peak (60% for the 65–74 and 75–84 age group and 50% for
the 85+ age group) during the 2003–2004 season. The annual
vaccination rate gradually dropped to 20–50% among three age
groups of the elderly (Fig 2C). Meanwhile, the increasing patterns
of hospitalization rates were also analyzed across all age strata. As
shown in Fig 2B, the rates gradually increased since the 1999–
2000 season and surged to the peak during the 2004–2005 season,
particularly in the both the 85+ and 75–84 age groups. Although
the patterns were also consistent throughout the study period, no
crossover of the hospitalization rates between the young and
elderly age groups was observed.
Propensity Score Model
The above crude comparison between P&I morbidity rate and
TIV vaccination coverage rate among the elderly during the
1999–2009 influenza seasons was confounded by various factors
which were unbalanced between groups with and without
receiving a TIV vaccination. In order to investigate the source
of bias affecting the temporal pattern of influenza-associated
morbidity, the logistic regression model was used to predict the
probability of receiving TIV vaccination annually. As different
people received TIV vaccination each season, the regression
model was performed annually and the details of the results after
model selection were summarized in Table S2 and S3. We found
that the selections of variables among the models were quite
consistent when fitting the regressions yearly from 1999–2000 to
2008–2009, with the only exception being the 1999–2000 season,
which had two variables that were not selected into the models,
including SES and having catastrophic illness.
The comparison shown in Table 1 was the summary result with
the range of odds ratios (ORs) from both uni-variate and
multivariate analysis. There were significant differences in the
distribution of geographic region, urbanization level, and SES
between the TIV receiving and non-receiving groups. The
vaccine-receiving group also had a higher prevalence of pre-
existing medical conditions, including numbers of comorbidities
(mean OR = 1.23, range:1.12–1.52, p,0.05), numbers of outpa-
tient visits during the past 5 years (mean OR = 1.02, range:1.02–
1.03, p,0.05) and recent intestinal disorder (mean OR = 1.56,
range:1.40–1.80, p,0.05), than the vaccine non-receiving group.
Additionally, the vaccine-receiving group had a lower prevalence
of URI OPD# in the previous year (mean OR = 0.89, range:0.85–
0.91, p,0.05) than the vaccine non-receiving group. Similar
results were observed for multivariate analysis (Table 1). Having
catastrophic illness showed a statistically significant difference in
prevalence between the vaccine-receiving group and the non-
receiving group with an average OR = 0.94 and range between
0.52 and 2.16, with higher prevalence in the vaccine-receiving
group in the year before the 2003–2004 season but lower
prevalence after the 2003–2004 season. After multivariate analysis,
the vaccine-receiving group had lower prevalence in having
catastrophic illness than the non-receiving group through all
influenza seasons except during the 1999–2000 (not selected by the
model) and 2000–2001 with OR = 1.74 (95% CI: 1.58–1.92). In
summary, the TIV-receiving group had a higher propensity score
than the non-receiving group (P,0.0001) (Fig 3).
Influenza-Associated Morbidity Models
In order to investigate the major factors affecting the temporal
pattern of influenza-associated morbidity, we then used the
propensity score as a summary confounder in a multivariate
Poisson regression model based on the trimmed data, which
included the strongest confounders along with the propensity
score. As shown in Table 2, two variables associated with the
temporal pattern of influenza-associated morbidity were calendar
year and month periods. Our analysis found that increased
calendar years were associated with decreased outpatient visits
with OR = 0.87 (95%CI: 0.86–0.87) but increased hospitalization
with OR = 1.13 (95%CI: 1.12–1.13) (p,0.001). Furthermore, the
annual influenza epidemic period, which usually occurs between
Oct. and Jan. in winter, showed higher influenza outpatient visits
with OR 1.22 (95%CI: 1.18–1.26) and 1.14 (95%CI: 1.08–1.19)
for month periods Sep.–Oct. and Nov.–Dec., respectively.
Conversely, the annual influenza epidemic period showed lower
influenza hospitalization risk with OR smaller than 1 compared
with the hospitalization rate during the month period of Jun.–
Aug.(Table 2), which was usually the baseline period in other
studies.
Our final model also found that increased age was associated
with decreased outpatient visits but increased hospitalization.
Compared to the age group 65–74, the higher the ages were, the
lower the risk of outpatients visits with OR = 0.85 (95%CI: 0.83–
0.87) and 0.62 (95%CI: 0.60–0.65) but the higher the risk of
hospitalization with OR = 2.36 (95%CI: 2.29–2.43) and 5.58
(95%CI: 5.35–5.82) for the age group 75–84 and $85, respec-
tively. Similarly, males were associated with decreased outpatient
visits with OR = 0.84 (95%CI: 0.83–0.86) but increased hospital-
ization with OR = 1.75 (95%CI: 1.70–1.79). Other factors that
were statistically significant in the Poisson model included co-
morbidity, vaccination rate, influenza virus type A and B isolation
rate, high propensity score, increased 1uC in temperature,
matching vaccine strains of H1N1 and type B. Among them, co-
morbidity, vaccination rate, influenza virus type A and B isolation
rate were associated with increased outpatient visits and hospital-
ization (p,0.05). In contrast, high propensity score, increased 1uC
in temperature, matching vaccine strains of type A/H1N1 and
type B were associated with decreased outpatient visits and
hospitalization with statistical significance (Table 2).
Influenza-associated excess morbidity in elderly
Examining the records from Table S1, five out of the ten studied
years showed early appearance of antigenic-drifted strains
including 2003-04 for H3N2, 1999–2000, 2004-05, 2005-06 and
2007-08 for both A subtypes (ie. H1N1 and H3N2), and 2006-07
for H1N1. Four among them appeared after 2004, which was
coincided with the declining vaccination rate among the elderly
with the peak shown in the 2003-04 season as shown in Fig 1. To
evaluate the epidemic excess morbidity in those years with early
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appearance of antigenic-drifted strain before the declining
vaccination rate in 2003 and after, we first reviewed the data on
the years with and without early appearance of antigenic-drifted
strain before the declining vaccination rate in 2003 (ie. without the
effect of declining vaccination rate). Then, we focused on the years
with early appearance of antigenic-drifted strain and compared
them before 2004 and after 2004 with the declining vaccination
rate (ie. to avoid the effect of early appearance of antigenic-drifted
strain).
First, when we examined the data on the years before 2004 (ie.
before the declining vaccination rate), only the 1999–2000 and
2003-04 seasons showed early appearances of antigenic-drifted
strains. The epidemic excess outpatient visits per 1,000 persons
during both seasons were 0.48 (95%CI: 0.33–0.62) and 0.50
(95%CI: 0.40–0.60), respectively and, which were no significantly
different from those during the 2001-02 season. However,
significantly higher hospitalizations were observed in 1999–2000
and 2003-04, where epidemic excess per 1,000 persons were 0.24
(95%CI: 0.22–0.25) and 0.28 (95%CI: 0.23–0.33), respectively,
compared to those during the 2000-03 seasons. Similar results
were also observed for annual excess with 0.53 (95%CI: 0.49–0.57)
and 0.49 per 1,000 (95% CI: 0.42–0.55) during the 1999–2000
and 2003-04 season, respectively, which were also higher than the
rest of the years.
Second, when we examined the years with early appearance of
antigenic-drifted strain and compared them before 2004 and after
2004, only one season (ie. 2003–2004 season) before 2004 but four
seasons (ie. 2004–2005, 2005–2006, 2006–2007, 2007–2008) after
2004 showed early appearance of antigenic-drifted strain. There-
fore, we included five seasons for comparison. Further examining
the mean value of epidemic and annual excess outpatient visits
before 2004 showed 0.50 (95%CI: 0.40–0.60) and 1.11 (95%CI:
0.98–1.25) per 1,000 persons, which was not significantly different
from those during the seasons after 2004. Similarly, no statistically
significant difference of the epidemic excess of hospitalization
between the seasons before 2004 and after 2004 was observed.
However, significantly lower annual excess of hospitalization with
0.49 (95%CI: 0.42–0.55) per 1,000 persons during the 2003–2004
season was observed compared to those during the seasons after
2004 (p,0.05).
In summary, substantial trends toward higher P&I hospitaliza-
tion were observed during the influenza season with early
appearance of antigenic-drifted strains.
Discussion
As worldwide influenza epidemics were considered to be seeded
each year by viruses that originated in East or Southeast Asia[22],
the early appearance of antigenic-drifted strain in this area posted
the threat of human health and vaccination strategy. However, no
study has been conducted to understand their impact on influenza-
associated morbidity. Each winter, most influenza morbidity and
deaths occur among seniors (although they were spared during the
2009 pandemic period)[23]. For nearly a decade, there has been a
controversy brewing about the benefits of vaccinating seniors
against influenza[4,24]. More recently analysis of influenza
morbidity and mortality time trends in several countries fueled
this concern, as these studies saw no decline in flu-related
hospitalization and deaths as vaccine coverage rose several fold
in seniors[7–9]. Our study confirmed that although higher
vaccination coverage rate was associated with higher morbidity,
there was lower probability of having influenza-associated
morbidity among those receiving TIV vaccination who yielded
higher propensity scores. Most importantly, the early appearances
of antigenic-drifted vaccine-mismatched strains after 2003 were
associated with higher morbidity among the elderly in Taiwan.
Increased vaccine accessibility for the elderly and timely identi-
fication of vaccine-mismatched circulating influenza viruses as well
as their antigenic variation is crucial for effective evidence-based
public health planning and preparedness.
The first and second aims of our study were to investigate the
temporal trend of influenza-associated morbidity including OPD
visits and hospitalization and identify source of bias affecting the
trend over a decade after the implementation of the free TIV
vaccination among the elderly since 1998. The dataset of NHI
covering 99% of the population in Taiwan thus avoided the
selection bias because of the insurance type. Two secular trends
were observed: (1) the outpatient visits showed a declining secular
trend but an increase in P&I associated hospitalization from both
the results of age direct-adjusted standardized rates and Poisson
regression model after adjusting various confounders; (2) the
decrease in the morbidity among the elderly (65–74 and 75–84),
which was lower than the young age group (5–19) after the 2003–
2004 season, was observed only in outpatient visit rates but not in
the hospitalization rates. In Taiwan, no free TIV vaccination was
provided for the 5–19 age group during the 1999–2006 seasons.
However, free TIV vaccination program was expanded to include
the 6–7 age group of grade 1–2 in the elementary school during
the 2007-08 and 2008-09 seasons. Therefore, the lower outpatient
visit among the 65–84 age groups could be due to the effect of TIV
vaccination. Previous studies from different populations and
countries have demonstrated the benefits of vaccination in the
elderly population during a single or 10 consecutive influenza
seasons with various vaccine effectiveness depending on the
matches between the vaccine and wild-type strain of influenza
virus although controversy remained regarding the association
between TIV and mortality [4,10,25–29]. Our study also
suggested profound effects of TIV in reducing the outpatient
visits among the elderly secularly. In contrast, the increasing trend
of hospitalization rate in this study was consistent with previous
publication[30]. Although the possibility of insurance cost to
encourage hospitalization has been considered, expenditures for
outpatient care exceeded inpatient care expenditures by a 2:1 ratio
after implementation of NHI in Taiwan based on the study by
Wen et al [31] and the most likely reason might be related to the
frailty among the elderly because of the deleterious immunological
function[32,33]. Based on our Poisson regression model, the oldest
age group (older than 84 years) had the highest risk of
hospitalization because of influenza compared to the age group
of 65–74 with OR = 5.58 (95%CI: 5.35–5.82). Similarly, the
elderly with co-morbidity was statistically significantly associated
with hospitalization with OR = 3.25 (95%CI: 3.15–3.35). On the
other hand, it was also plausible that other confounding variables
resulted in ecological fallacy, such as ‘‘healthy-vaccinee ef-
fect’’[34], the geographic variations and disparities in vaccine
delivery and vaccination rates[35], the aging of the popula-
tion[33], or the increasing numbers of elderly persons with high-
risk conditions for whom the risk of dying increases exponential-
ly[36]. Our study used the propensity score to mitigate the
problem of bias. Furthermore, methodological research has shown
that calculating propensity scores does provide the ability to
identify outliers outside the central distribution of the other group,
and trimming improves the validity by restricting the study to
comparable observations[21]. Our study found that although
higher vaccination rates were associated with higher morbidity in
hospitalization, there was a lower probability of having influenza-
associated morbidity among those receiving TIV vaccination that
yielded higher propensity score. This could be due to patients with
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higher propensity scores tending to be more vulnerable to
influenza and having more contact with providers who encourage
vaccination. A previous study suggested that incomplete matched
influenza vaccine still provide protection in frail elderly[37].
Therefore, our study did not only identify the important sources of
bias when analyzing the secular trend of P&I-associated morbidity,
but also strengthened the necessity of TIV vaccination among the
elderly including the frail persons.
Several observational studies have noticed that morbidity and
mortality were relatively low in vaccinees even before the start of
flu seasons and suggested the differences in mortality among
vaccinated vs unvaccinated is attributable to selection bias[38,39].
They used the time period during the influenza season and outside
influenza season, which are referred to as difference-in-differences
approach, to trace the trajectory of the bias over time[40].
However, this approach was difficult to implement in the sub-
tropical countries in Southeast Asia where the influenza season
was not easily defined and summer influenza epidemics were
common as shown in Fig 1 and Table S1. Additionally, the
specificity of disease classification based on ICD-9-CM usually
presented a problem in many observational studies[30,41]. In our
study, we included the virus isolation rates of type A and B of
influenza virus to increase the model fitting and the temporal trend
based on the predicted model results demonstrated comparable
peaks between the observed and predicted values, even during the
peak of summer flu as shown in Fig 1. Interestingly, we found that
our data suggested using months Jun-Aug as a baseline, the
morbidity of the other months was lower only in outpatient visits
but hospitalization in contrast was higher. Our study suggested
that there is relative difficulty in conducting a vaccine effectiveness
study using observational data in sub-tropical countries in
Southeast Asia and more sophisticated epidemiological methods
are required in the future.
The third aim of our study, which is also the first study to our
knowledge, was to investigate the impact of early appearance of
vaccine-mismatched strains on influenza-associated morbidity.
Two findings were presented here: (1) the mismatches between the
vaccine and wild-type strains, particularly type A H1N1 and type
B, were associated with the P&I-associated hospitalization with
OR = 0.76 (95%CI: 0.73–0.79) and 0.95 (95%CI: 0.92–0.98),
respectively, but not with outpatient visits (Table 2); (2) by either
examining the peak excess morbidity in those years with early
appearance of antigenic-drifted strain before the declining
vaccination rate in 2003 or comparing them before and after
2004, higher P&I hospitalizations were observed during the
influenza seasons with early appearance of antigenic-drifted strains
(Table 3). TIVs are most effective when there is a good match
between circulating viruses and vaccine strains; protection may
also be substantial, though sometimes lower, during years with a
poor match among healthy adults, elderly at high risk or
institutionalized[25–27]. More importantly, the early appearance
of vaccine-mismatched strains of influenza virus presented a large
medical burden of health in the elderly.
Our data and findings have limitations. First, potential missing
data on flu shots given without registry on the insurance card was
possible. However, it won’t largely affect the results since the
vaccination rates derived from NHIRD during the study period
were consistent with the governmental registry data organized by
Taiwan-CDC (data not shown). Second, we only used variables
obtained from the NHIRD for propensity score calculation to
adjust the care-seeking behavior, which may vary across social-
cultural settings and practice settings. Third, physical functionality
is an important confounder [33,42] and we only used propensity
score as a proxy to measure the functionality. Fourth, smoking
status was not available. It is well known that individuals who
receive influenza vaccinations are less likely to smoke than
individual who do not, and that smokers are more likely to get
Figure 2. Age-specific event rates over the study period from 1999–2000 to 2008–2009 influenza seasons in Taiwan. Panel A and
Panel B represents pneumonia and influenza (P&I)-related outpatient visit and hospitalization rates. Panel C represents the annual trivalent influenza
vaccine (TIV) vaccination rate in percentage.
doi:10.1371/journal.pone.0084239.g002
Figure 3. Predicted propensity scores between TIV-receiving and TIV non-receiving elderly over the study period from 1999–2000
to 2008–2009 influenza seasons in Taiwan.
doi:10.1371/journal.pone.0084239.g003
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influenza[39,43]. Fifth, other unknown variables including the
contact patterns among the elderly, anxiety over side effects,
disease threat perception, and benefits education provided were
not available.
In summary, our study investigated the temporal trend of
influenza-associated morbidity including OPD visits and hospital-
ization, and source of bias to correlate the vaccination rates and
morbidity data over a decade after the implementation of the free
TIV vaccination among the elderly since 1998. Most importantly,
the early appearance of antigenic-drifted strains of influenza
viruses was correlated with the increased risk of P&I-associated
hospitalization among the elderly. A vaccine efficacy/effectiveness
study will be important to confirm this result in the future.
Achieving optimal success in preventing and controlling influenza
among the elderly may require more immunogenic vaccines which
are still under development and have not yet been approved for
use. Vaccination of school-aged children has been suggested to be
associated with lower morbidity and mortality among the elderly
in the community[44–47]. However, these studies are not
conclusive and additional research is needed to define the benefits
among the elderly. In the meantime, vaccination rates of elderly
persons remain stagnant and well below 50%. The health care
providers and policymakers should renew efforts to improve the
delivery of current influenza vaccines to the elderly, particularly
the group with high propensity score. Additionally, the inclusion of
local strains which appeared antigenic-drifted based on the
surveillance system in the composition of TIV among the elderly
warrants careful consideration particularly in East or Southeast
Asian countries.
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Table 1. Demographic characteristics and comorbidity
medical disorders between TIV-receive and non-receive
groups among the elderly $65 in years by propensity score
logistic regression model.
ORb Adjust ORb
Mean Min Max Mean Min Max
Geographic region
North 1.00 1.00 1.00 1.00 1.00 1.00
Central 1.60* 1.22 2.15 1.27* 0.96 1.85
South 1.38* 1.20 1.58 1.15* 1.05 1.38
East 1.28* 1.12 1.63 0.95# 0.83 1.48
Urbanization level
1 (Most urbanized) 0.61* 0.50 0.75 0.65* 0.53 0.77
2 0.75* 0.66 0.88 0.75* 0.65 0.89
3 0.84# 0.76 1.02 0.86* 0.77 1.11
4 1.00 1.00 1.00 1.00 1.00 1.00
5 1.18* 0.72 1.38 1.15* 0.67 1.35
6 (Least urbanized) 1.17* 1.08 1.47 1.16* 1.09 1.42
Socioeconomic status
low 1.00 1.00 1.00 1.00 1.00 1.00
moderate 0.84* 0.68 0.96 1.08# 0.89 1.24
high 0.68* 0.56 0.84 0.83# 0.70 0.99
URI OPD# in prior 1 yeara 0.89* 0.85 0.91 0.84* 0.80 0.86
Outpatient visit frequency 1.02* 1.02 1.03 1.04* 1.03 1.04
Number of Comorbidities 1.23* 1.12 1.52 1.11* 1.01 1.35
Catastrophic Illness 0.94* 0.52 2.16 0.77# 0.40 1.74
Recent Intestinal Disorder 1.56* 1.40 1.80 1.39* 1.12 1.69
aURI OPD: outpatient visits due to upper respiratory infections;
bOR: odds ratio by univariate and multivariate logistic regression;
*p,0.05 throughout all influenza years from 1999–2000 to 2008–2009;
#p,0.05 throughout all influenza years except year 1999–2000.
doi:10.1371/journal.pone.0084239.t001
Table 2. Primary analysis results of two fitted multivariate
Poisson regression models for pneumonia/influenza-
associated outpatient visits and hospitalization among the
elderly from Sep., 1999 to Aug., 2009.
Parameter Outpatient Hospitalization
OR 95% CI OR 95% CI
Age
65–74 1.00 (reference) 1.00 (reference)
75–84 0.85** (0.83,0.87) 2.36** (2.29,2.43)
85+ 0.62** (0.60,0.65) 5.58** (5.35,5.82)
Sex
Female 1.00 (reference) 1.00 (reference)
Male 0.84** (0.83,0.86) 1.75** (1.70,1.79)
Comorbidity 1.15** (1.13,1.17) 3.25** (3.15,3.35)
Propensity Score
1(Lowest) 1.00 (reference) 1.00 (reference)
2 0.66** (0.64,0.68) 0.67** (0.64,0.70)
3 0.78** (0.76,0.81) 0.65** (0.62,0.68)
4 1.05** (1.03,1.08) 0.69** (0.66,0.72)
5(Highest) 1.74** (1.70,1.79) 0.86** (0.83,0.89)
Year 0.87** (0.86,0.87) 1.13** (1.12,1.13)
Period
Jun–Aug 1.00 (reference) 1.00 (reference)
Sep–Oct 1.22** (1.18,1.26) 0.86** (0.82,0.90)
Nov–Dec 1.14** (1.08,1.19) 0.81** (0.75,0.87)
Jan–Feb 0.95 (0.89,1.01) 0.84** (0.77,0.92)
Mar–May 1.09** (1.05,1.14) 0.99 (0.94,1.05)
Temperature 1.00** (1.00,1.00) 1.01** (1.01,1.01)
Vaccination Rate 0.96* (0.96,0.97) 0.98** (0.97,0.99)
INFA Isolation Rate 1.01** (1.01,1.01) 1.01** (1.00,1.01)
INFB Isolation Rate 1.00* (1.00,1.00) 1.00* (1.00,1.01)
A/H1N1Vaccine Strain Matching 1.00 (0.97,1.03) 0.76** (0.73,0.79)
A/H3N2Vaccine Strain Matching 0.99 (0.97,1.02) 1.01 (0.97,1.06)
INF B Vaccine Strain Matching 0.98 (0.96,1.00) 0.95* (0.92,0.98)
*p,0.05;
**p,0.001.
doi:10.1371/journal.pone.0084239.t002
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Table S3 Annual adjusted analysis results of multivariate
propensity logistic regression models from 1999–2000 to 2008–
2009 influenza seasons.
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